文献速递认知障碍与痴呆

轻度认知障碍疑似非阿尔茨海默病病理的神经退行性变与APOE基因型

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
PubMed 文献 · JAMA Neurol · 2017-01-01

该纵向队列研究比较了轻度认知障碍(MCI)中β-淀粉样蛋白阴性但神经退行性变阳性(SNAP)与β-淀粉样蛋白阳性且神经退行性变阳性(Aβ+N+)患者的神经退行性变模式和认知结局。结果显示,MCI的SNAP亚型相比Aβ+N+ counterpart,颞顶叶FDG代谢保留更好、颞叶外侧萎缩更轻、脑脊液tau水平更低,且APOE ε4携带率更低、APOE ε2携带率更高,认知下降更慢、进展为阿尔茨海默病的比例更低。在认知正常个体中,Aβ-N+与Aβ+N+的神经退行性变生物标志物无差异。

要点

  • MCI的SNAP患者相比Aβ+N+患者,颞顶叶FDG代谢更好、颞叶萎缩更轻、脑脊液tau更低。
  • MCI的SNAP患者APOE ε4携带率低而ε2携带率高,认知下降更慢、进展为AD比例更低。
  • 认知正常人群中,Aβ-N+与Aβ+N+的神经退行性变生物标志物无显著差异。

核心结论

  • 在MCI的SNAP患者中,低APOE ε4和高APOE ε2携带率可能解释Aβ-N+与Aβ+N+之间神经退行性变模式的差异,且独立于定义神经退行性变的影像学生物标志物模态。

研究设计与样本

  • 纵向队列研究,纳入2005年8月1日至2015年6月30日期间在美国和加拿大阿尔茨海默病神经影像学倡议站点接受照护的轻度认知障碍患者和认知正常个体,平均随访30.5个月。
  • 共纳入265名认知正常个体(135名女性,130名男性;平均[SD]年龄75.5[6.7]岁)和522名MCI患者(225名女性,297名男性;平均[SD]年龄72.6[7.8]岁)。

主要发现

  • 在MCI患者中,107例为Aβ-N+(22.8%;63例FDG+,82例HV+,38例FDG+HV+),187例为Aβ+N+(39.9%;135例FDG+,147例HV+,95例FDG+HV+)。
  • 在认知正常个体中,52例为Aβ-N+(24.9%;30例FDG+,33例HV+,11例FDG+HV+),37例为Aβ+N+(17.7%;22例FDG+,26例HV+,11例FDG+HV+)。
  • MCI的SNAP亚型相比Aβ+N+ counterpart,颞顶叶FDG代谢保留更好(平均[SD] FDG:Aβ-N+ 1.25[0.11] vs Aβ+N+ 1.19[0.11]),颞叶外侧萎缩更轻,脑脊液tau水平更低(平均[SD] 59.2[32.8] vs 111.3[56.4])。
  • MCI的SNAP患者中,APOE ε4携带率更低(Aβ-N+ 18.7% vs Aβ+N+ 70.6%),APOE ε2携带率更高(18.7% vs 4.8%)。
  • MCI的SNAP患者认知下降更慢,进展为阿尔茨海默病的比例更低(Aβ-N+ 6.5% vs Aβ+N+ 32.6%)。

关键数值与推荐

  • SNAP定义为Aβ阴性且神经退行性变阳性(Aβ-N+),神经退行性变阳性包括FDG PET颞顶叶葡萄糖代谢低于阈值(FDG+)和/或MRI海马体积低于阈值(HV+)。

临床怎么用

  • 对于MCI患者,若Aβ生物标志物阴性但神经退行性变标志物阳性(SNAP),应考虑到其神经退行性变程度较轻、认知预后较好,可能与APOE ε2保护作用相关。
  • 在解读MCI患者的神经退行性变生物标志物时,应结合APOE基因型,因其可能影响神经退行性变模式及疾病进展速度。

局限性

  • 本研究未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are conflicting results claiming that Alzheimer disease signature neurodegeneration may be more, less, or similarly advanced in individuals with β-amyloid peptide (Aβ)-negative (Aβ-) suspected non-Alzheimer disease pathophysiology (SNAP) than in Aβ-positive (Aβ+) counterparts. OBJECTIVE: To examine patterns of neurodegeneration in individuals with SNAP compared with their Aβ+ counterparts. DESIGN, SETTING, AND PARTICIPANTS: A longitudinal cohort study was conducted among individuals with mild cognitive impairment (MCI) and cognitively normal individuals receiving care at Alzheimer's Disease Neuroimaging Initiative sites in the United States and Canada for a mean follow-up period of 30.5 months from August 1, 2005, to June 30, 2015. Several neurodegeneration biomarkers and longitudinal cognitive function were compared between patients with distinct SNAP (Aβ- and neurodegeneration-positive [Aβ-N+]) subtypes and their Aβ+N+ counterparts. MAIN OUTCOMES AND MEASURES: Participants were classified according to the results of their florbetapir F-18 (Aβ) positron emission tomography and their Alzheimer disease-associated neurodegeneration status (temporoparietal glucose metabolism determined by fluorodeoxyglucose F 18 [FDG]-labeled positron emission tomography and/or hippocampal volume [HV] determined by magnetic resonance imaging: participants with subthreshold HV values were regarded as exhibiting hippocampal volume atrophy [HV+], while subthreshold mean FDG values were considered as FDG hypometabolism [FDG+]). RESULTS: The study comprised 265 cognitively normal individuals (135 women and 130 men; mean [SD] age, 75.5 [6.7] years) and 522 patients with MCI (225 women and 297 men; mean [SD] age, 72.6 [7.8] years). A total of 469 individuals with MCI had data on neurodegeneration biomarkers; of these patients, 107 were Aβ-N+ (22.8%; 63 FDG+, 82 HV+, and 38 FDG+HV+) and 187 were Aβ+N+ (39.9%; 135 FDG+, 147 HV+, and 95 FDG+HV+ cases). A total of 209 cognitively normal participants had data on neurodegeneration biomarkers; of these, 52 were Aβ-N+ (24.9%; 30 FDG+, 33 HV+, and 11 FDG+HV+) and 37 were Aβ+N+ (17.7%; 22 FDG+, 26 HV+, and 11 FDG+HV+). Compared with their Aβ+ counterparts, all patients with MCI SNAP subtypes displayed better preservation of temporoparietal FDG metabolism (mean [SD] FDG: Aβ-N+, 1.25 [0.11] vs Aβ+N+, 1.19 [0.11]), less severe atrophy of the lateral temporal lobe, and lower mean (SD) cerebrospinal fluid levels of tau (59.2 [32.8] vs 111.3 [56.4]). In MCI with SNAP, sustained glucose metabolism and gray matter volume were associated with disproportionately low APOE ε4 (Aβ-N+, 18.7% vs Aβ+N+, 70.6%) and disproportionately high APOE ε2 (18.7% vs 4.8%) carrier prevalence. Slower cognitive decline and lower rates of progression to Alzheimer disease (Aβ-N+, 6.5% vs Aβ+N+, 32.6%) were also seen in patients with MCI with SNAP subtypes compared with their Aβ+ counterparts. In cognitively normal individuals, neurodegeneration biomarkers did not differ between Aβ-N+ and Aβ+N+ cases. CONCLUSIONS AND RELEVANCE: In MCI with SNAP, low APOE ε4 and high APOE ε2 carrier prevalence may account for differences in neurodegeneration patterns between Aβ-N+ and Aβ+N+ cases independent from the neuroimaging biomarker modality used to define neurodegeneration associated with Alzheimer disease.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Schreiber S, Schreiber F, Lockhart SN, et al. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology. JAMA Neurol. 2017. PMID: 28319241. doi:10.1001/jamaneurol.2016.5349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。